Ardelyx, Inc. (ARDX) vs Geron Corporation (GERN)

Ardelyx, Inc. and Geron Corporation are both Biotechnology companies. Ardelyx, Inc. and Geron Corporation are of similar size ($814.9M and $790.2M). Geron Corporation grew revenue faster over the last twelve months: 24.4% against 16.8%. Ardelyx, Inc. has the higher net margin (−12.4% vs −33.1%) and the higher return on invested capital (−18.6% vs −89.9%). Across the 18 metrics below, Ardelyx, Inc. leads on 11 and Geron Corporation on 7.

Valuation

Metric ARDX GERN Biotechnology median
P/E n/m n/m 8.50
P/S 1.70 3.84 9.71
P/B 5.14 3.59 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1.69 3.29 9.21
Earnings yield (7.25%) (9.01%) (33.15%)
Free cash flow yield (2.34%) (14.62%) (25.50%)

Profitability

Metric ARDX GERN Biotechnology median
Gross margin 94.37% 93.51% 65.16%
Operating margin (7.86%) (25.31%) 0.00%
Net margin (12.35%) (33.05%) 0.00%
Free cash flow margin (3.97%) (56.10%) 0.00%
Return on equity (38.61%) (28.28%) (56.36%)
Return on assets (10.68%) (12.59%) (48.04%)
Return on invested capital (18.62%) (89.85%) 0.00%

Growth

Metric ARDX GERN Biotechnology median
Revenue growth (TTM) 16.77% 24.39% 6.02%
EPS growth (last fiscal year) (52.94%) 51.85% 30.26%
Revenue growth, 5-year CAGR 121.90% 273.49% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARDX GERN Biotechnology median
Debt to equity 1.69 0.55 0.00
Current ratio 3.34 6.92 4.72
Net debt to EBITDA 1.63 3.28 0.96

Dividend

Metric ARDX GERN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ARDX GERN Biotechnology median
Market cap 814.85m 790.24m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack